CCEL up today per today's release that they closed their deal with Duke licensing the commercialization of Duke's umbilical cord blood and tissue trials for Autism, arthritis and many others. With market cap of less than $100 million, could be huge upside if the market gives a biotech valuation to the assets like MESO with $1.7 billion market cap.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.